All In Biotech

NDA 020844 · Janssen Pharms

Topamax Sprinkle

Topiramate · Oral

Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Oct 26, 1998

Approved uses

11

Original approval plus efficacy supplements

Registered trials

302

82 Phase 3, 10 recruiting

FAERS reports

92,148

64,116 serious, 7,028 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 12, 2026.

TOPAMAX is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy TOPAMAX is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy TOPAMAX is indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. 1.3 Migraine TOPAMAX is indicated for the preventive treatment of migraine in patients 12 years of age and older.

Mechanism: The precise mechanisms by which topiramate exerts its anticonvulsant and preventive migraine effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy and the preventive treatment of migraine. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • TOPAMAX SPRINKLE · TOPIRAMATE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
  • TOPAMAX · TOPIRAMATE 15MG · CAPSULE, ORAL · Prescription · TE AB
  • TOPAMAX · TOPIRAMATE 25MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Topiramate" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective10,548
  • off label use7,681
  • headache6,623
  • nausea6,046
  • fatigue5,536
  • pain4,701
  • migraine4,500
  • dizziness4,290
  • seizure3,887
  • diarrhoea3,826
  • vomiting3,773
  • depression3,718

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,032
20051,462
20061,578
20071,391
20081,612
20092,237
20102,824
20113,117
20123,489
20133,185
20143,698
20155,908
20166,576
20175,198
20186,041
20196,491
20205,713
20215,342
20225,096
20235,154
20245,748
20255,583
20263,668

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Topamax (Topiramate)

2024 spending

$41.4M

Beneficiaries

3,052

21,528 claims

Per beneficiary

$13,559

$15.99 per unit

View as table
YearSpending
2020$53,016,267
2021$51,155,755
2022$49,599,409
2023$47,505,378
2024$41,380,829

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,003 on PubMed

Sponsor: Johnson & Johnson (Janssen) · Also marketed as Topamax

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.